

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P O Box 1450 Alexandra, Virgina 22313-1450 www.spile.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/966,447	09/28/2001	David Christian Lentz	CRD0957USNP	2148		
27777 PHILIP S. JOH	7590 07/14/2011 HNSON	EXAMINER				
JOHNSON &	JOHNSON	RYCKMAN, MELISSA K				
	ON & JOHNSON PLAZA WICK, NJ 08933-7003	A	ART UNIT	PAPER NUMBER		
	The stories were the stories and the stories and the stories and the stories are stories a			3773		
			NOTIFICATION DATE	DELIVERY MODE		
			07/14/2011	ELECTRONIC		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

jnjuspatent@corus.jnj.com lhowd@its.jnj.com gsanche@its.jnj.com

Advisory Action Before the Filing of an Appeal Brief

Application No.		Applicant(s)		
	09/966,447	LENTZ ET AL.		
	Examiner	Art Unit		
	MELISSA RYCKMAN	3773		

3 ,,	LAGIIIIICI	ALC OILL	1					
	MELISSA RYCKMAN	3773						
-The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
THE REPLY FILED 30 June 2011 FAILS TO PLACE THIS APP	PLICATION IN CONDITION FOR A	LLOWANCE.						
The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of thi application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFI 3.13 or (3) a Request for Continued Examination (RCE) in compliance with 37 CFI 1.114. The reply must be filed within one of the following time periods:								
a) The period for reply expiresmonths from the mailing	g date of the final rejection.							
b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.								
Examiner Note: If box 1 is checked, check either box (a) or MONTHS OF THE FINAL REJECTION. See MPEP 706.07(Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN T							
Extensions of time may be obtained under 37 CFR 1.138(a). The date have been filled is the date for purposes of determining the period value of 27 CFR 1.17(a) is calculated from (1) the expiration date of the valued a7 CFR 1.17(a) is calculated from (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office armay reduce any earmed patient term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL.	on which the petition under 37 CFR 1.1 tension and the corresponding amount shortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as					
The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte Notice of Appeal has been filed, any reply must be filed was the notice of Appeal has been filed, any reply must be filed was the notice of Appeal has been filed, any reply must be filed was the notice of Appeal has been filed, any reply must be filed was the notice of Appeal has been filed.	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	of the date of appeal. Since					
AMENDMENTS	ann are anne period est iotal in er	o						
3. \(\sum \) The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) \(\sum \) They raise new issues that would require further consideration and/or search (see NOTE below); (b) \(\sum \) They raise the issue of new matter (see NOTE below);								
	(c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for							
(d) They present additional claims without canceling a		ected claims.						
NOTE: See Continuation Sheet. (See 37 CFR 1.1								
 The amendments are not in compliance with 37 CFR 1.1. 		mpliant Amendment (PTOL-324).					
 Applicant's reply has overcome the following rejection(s) 								
 Newly proposed or amended claim(s) would be al non-allowable claim(s). 	·		_					
7. Solution For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is protected in the status of the claim(s) is (or will be) as follows:		l be entered and an e	cplanation of					
Claim(s) allowed: Claim(s) objected to:								
Claim(s) rejected: <u>1</u> . Claim(s) withdrawn from consideration: <u>18 and 20-34</u> .								
AFFIDAVIT OR OTHER EVIDENCE								
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 								
The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to conshowing a good and sufficient reasons why it is necessary.	vercome <u>all</u> rejections under appea y and was not earlier presented. Se	al and/or appellant fail: se 37 CFR 41.33(d)(1	s to provide a).					
10. The affidavit or other evidence is entered. An explanatio	n of the status of the claims after er	ntry is below or attach	ed.					
REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but	t does NOT place the application in	condition for allowan	ce because:					
12. Note the attached Information Disclosure Statement(s). 13. Other:	(PTO/SB/08) Paper No(s)							
/CORRINE M MCDERMOTT/ Supervisory Patent Examiner, Art Unit 3773	/Melissa Ryckman/ Examiner, Art Unit 3773							

Continuation of 3, NOTE: the addition of the weight of the biocompatible layer being about 0.4% to about 10% by weight requires further search and consideration.